DNA Damage Proteins and Response to Therapy in Head and Neck Cancer
作者： Ranee Mehra , Ilya G. Serebriiskii
DOI: 10.1007/978-1-4614-8815-6_13
关键词:
摘要: DNA-damaging agents such as cisplatin and radiotherapy have provided a cornerstone of treatment for squamous cell cancers the head neck (SCCHN). Cells possess multiple mechanisms repairing different classes DNA damage, including base excision repair (BER), nucleotide (NER), mismatch (MMR), resolution intrastrand cross-linking by Fanconi anemia (FA) proteins, nonhomologous end joining (NHEJ), homologous recombination (HR). Preclinical limited degree clinical research has focused on evaluating whether changes in expression, mutation, or polymorphic variants many enzymes involved these pathways are resistance SCCHN. This chapter will first summarize proteins functioning complementary DNA-damage response pathways, then focus current data regarding their prognostic value clinic, noting limitations retrospective evaluations, discussing implications future research.
springer.com
elsevier.com
sci-hub.st 参考文章(106)
ERCC1 and non-small-cell lung cancer [8] The New England Journal of Medicine. ,vol. 356, pp. 2538- 2540 ,(2007) , 10.1056/NEJMC070742
Nikolaos Zamboglou, George Fountzilas, Thomas Zaramboukas, Anna Kalogera-Fountzila, Konstantine T Kalogeras, Paris Kosmidis, Georgia Karayannopoulou, Mattheos Bobos, Eleni Athanassiou, Despina Misailidou, Aristotelis Bamias, Pavlos Papakostas, Christos Tolis, Periklis Tsekeris, Chrysanthi Vamvouka, Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck Anticancer Research. ,vol. 29, pp. 529- 538 ,(2009)
A. E. Vidal, XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions The EMBO Journal. ,vol. 20, pp. 6530- 6539 ,(2001) , 10.1093/EMBOJ/20.22.6530
Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445
Benjamin J Moeller, John S Yordy, Michelle D Williams, Uma Giri, Uma Raju, David P Molkentine, Lauren A Byers, John V Heymach, Michael D Story, J Jack Lee, Erich M Sturgis, Randal S Weber, Adam S Garden, K Kian Ang, David L Schwartz, None, DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy Clinical Cancer Research. ,vol. 17, pp. 2035- 2043 ,(2011) , 10.1158/1078-0432.CCR-10-2641
Tanya M. Gottlieb, Stephen P. Jackson, The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen Cell. ,vol. 72, pp. 131- 142 ,(1993) , 10.1016/0092-8674(93)90057-W
Kazuhiko Uchida, Masanao Miwa, Poly(ADP-ribose) polymerase: structural conservation among different classes of animals and its implications. Molecular and Cellular Biochemistry. ,vol. 138, pp. 25- 32 ,(1994) , 10.1007/BF00928439
H J Jun, M J Ahn, H S Kim, S Y Yi, J Han, S K Lee, Y C Ahn, H-S Jeong, Y-I Son, J-H Baek, K Park, ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. British Journal of Cancer. ,vol. 99, pp. 167- 172 ,(2008) , 10.1038/SJ.BJC.6604464
David Murray, Elizabeth Rosenberg, The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutation Research-dna Repair. ,vol. 364, pp. 217- 226 ,(1996) , 10.1016/S0921-8777(96)00036-5
Mary-Beth Moore Joshi, Yoshinori Shirota, Kathleen D. Danenberg, Debbi H. Conlon, Dennis S. Salonga, James E. Herndon, Peter V. Danenberg, David H. Harpole, High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clinical Cancer Research. ,vol. 11, pp. 2215- 2221 ,(2005) , 10.1158/1078-0432.CCR-04-1387